Bausch Health Companies (NYSE:BHC) Upgraded at StockNews.com

StockNews.com upgraded shares of Bausch Health Companies (NYSE:BHC) from a hold rating to a buy rating in a research note issued to investors on Saturday morning.

A number of other equities analysts also recently commented on the stock. Raymond James initiated coverage on shares of Bausch Health Companies in a research note on Wednesday, July 10th. They set a market perform rating and a $8.00 price objective for the company. Royal Bank of Canada cut their target price on shares of Bausch Health Companies from $12.00 to $11.00 and set a sector perform rating for the company in a research note on Tuesday, April 23rd. Truist Financial cut their target price on shares of Bausch Health Companies from $8.00 to $7.00 and set a hold rating for the company in a research note on Thursday, July 25th. Finally, Piper Sandler raised their target price on shares of Bausch Health Companies from $7.00 to $9.00 and gave the company a neutral rating in a research note on Monday, April 29th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of Hold and a consensus target price of $9.80.

Bausch Health Companies Trading Down 0.7 %

Shares of NYSE BHC opened at $5.95 on Friday. The firm has a market cap of $2.15 billion, a PE ratio of -4.80 and a beta of 0.77. Bausch Health Companies has a 1-year low of $3.96 and a 1-year high of $11.46. The company has a fifty day moving average price of $6.71 and a 200 day moving average price of $7.99.

Bausch Health Companies (NYSE:BHC) last posted its quarterly earnings data on Thursday, May 2nd. The company reported $0.59 EPS for the quarter, missing analysts’ consensus estimates of $0.75 by ($0.16). Bausch Health Companies had a negative return on equity of 2,370.91% and a negative net margin of 5.07%. The business had revenue of $2.15 billion for the quarter, compared to analyst estimates of $2.18 billion. Equities research analysts forecast that Bausch Health Companies will post 3.6 EPS for the current year.

Institutional Investors Weigh In On Bausch Health Companies

Hedge funds have recently bought and sold shares of the company. Salem Investment Counselors Inc. bought a new position in Bausch Health Companies in the 1st quarter valued at about $32,000. Principal Securities Inc. bought a new position in Bausch Health Companies in the 4th quarter valued at about $31,000. Tower Research Capital LLC TRC raised its holdings in Bausch Health Companies by 283.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,918 shares of the company’s stock valued at $55,000 after acquiring an additional 5,112 shares during the period. Bfsg LLC bought a new position in Bausch Health Companies in the 4th quarter valued at about $63,000. Finally, Citigroup Inc. raised its holdings in Bausch Health Companies by 73.3% in the 3rd quarter. Citigroup Inc. now owns 20,820 shares of the company’s stock valued at $172,000 after acquiring an additional 8,804 shares during the period. 78.65% of the stock is currently owned by institutional investors and hedge funds.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.